Sign inJoin waitlistJoin the waitlist

Suhu Liu

Clinical Assistant Professor in Medicine · Stony Brook Medicine

Credentials: · · · · · ·

History

Stony Brook Medicine
Present

Hematology and Medical Oncology
Stony Brook Medicine
2020–2023
Internal Medicine
Montefiore Medical Center/Albert Einstein College of Medicine
2017–2020
Doctor of Medicine
1995–1999

Research

The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis
BMC Medical Genomics · 2008 · 429 citations
STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-κB to IL-6 signaling axis and STAT3-driven cancer phenotypes
Science Signaling · 2014 · 146 citations
Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling
Pigment Cell & Melanoma Research · 2008 · First of 5 authors · 103 citations

Adam Riker
12 papers
David Frank
12 papers
Jennifer Yeh
4 papers · 1 as a resident
Michael Xiang
4 papers · 2 as a resident
Helen Gandler
2 papers
Hung Khong
2 papers
JB
James Bradner
2 papers
Richard Stone
2 papers
Adil Daud
1 paper
Ahmed Qavi
1 paper · 1 as a fellow
Andrea Richardson
1 paper
Ann Mullally
1 paper

Clinical trials

Acute Myeloid Leukemia and Markers of Leukemia Stem Cells (CLL1 and CD45RA)
Principal investigator · Recruiting
Suhu Liu
2024–2027
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029